Erica L. Mayer, MD, MPH

The panel applies the treatment framework to clinical scenarios involving patients with hormone receptor-positive, HER2-negative metastatic breast cancer (HR+/HER2− mBC) after progression on first-line CDK4/6 inhibitor plus endocrine therapy.

The panel focuses on multidisciplinary monitoring and proactive toxicity management for patients with hormone receptor-positive, HER2-negative metastatic breast cancer (HR+/HER2− mBC), particularly as treatment moves into later-line targeted therapy.

The panel discusses the clinical and practical considerations surrounding the introduction of gedatolisib for patients with hormone receptor-positive, HER2-negative metastatic breast cancer (HR+/HER2− mBC), with particular emphasis on its mechanism, toxicity profile, intravenous administration, and patient education.

The panel examines the VIKTORIA-1 study and its implications for treatment selection in hormone receptor-positive, HER2-negative metastatic breast cancer (HR+/HER2− mBC) after CDK4/6 inhibitor therapy.

The panel examines how emerging endocrine doublets and earlier biomarker monitoring could reshape treatment sequencing for patients with hormone receptor-positive, HER2-negative metastatic breast cancer (HR+/HER2− mBC).

The panel discusses the patient experience when transitioning between therapies and routes of administration in hormone receptor-positive, HER2-negative metastatic breast cancer (HR+/HER2− mBC).

The panel explores treatment selection for patients with hormone receptor-positive, HER2-negative metastatic breast cancer (HR+/HER2− mBC) harboring both ESR1 and PI3K pathway alterations, emphasizing the need to individualize therapy according to disease biology, pace, symptoms, and treatment tolerability.

The panel shifts to treatment strategies for patients with hormone receptor-positive, HER2-negative metastatic breast cancer (HR+/HER2− mBC) who develop an ESR1 mutation after progression on an aromatase inhibitor plus CDK4/6 inhibitor.

Erica L. Mayer, MD, MPH, discussed the practical questions clinicians must answer as the SERENA-6 early-switch approach with camizestrant enters practice.

Erica L. Mayer, MD, MPH, explained why oncologists should switch to camizestrant at ESR1 mutation emergence rather than reserve oral SERDs for progression.

Clinicians weigh alpelisib’s hyperglycemia, rash, diarrhea and increasingly favor capivasertib for lower glucose risk with close monitoring.

Explore evolving options for biomarker-negative metastatic breast cancer, from CDK4/6 rechallenge to gadeptolizumab and PAM-pathway targeted therapy.

Learn how liquid and tissue biopsies uncover ESR1 and PI3K mutations to personalize metastatic breast cancer second-line therapy choices.

Learn how biomarker testing guides second-line choices after CDK4/6 therapy in HR+ HER2- metastatic breast cancer, including PI3K/AKT/mTOR options.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.

The expert explained her research focused on the role of CDK4/6 inhibitors in treating breast cancer.